ICMJE DISCLOSURE FORM

Date: Nov 1, 2021

Your Name: Chen Xinrui

Manuscript Title: Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | ___ ___ None | Jiangsu Fosun Pharmaceutical Sales Co. Ltd. No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |
|   | Time frame: Since the initial planning of the work | | |
|2 | Grants or contracts from any entity (if not indicated in item #1 above). | X X None | |
|3 | Royalties or licenses | X X None | |

|   | Time frame: past 36 months | | |
|   | Statement                                                                 |   |
|---|---------------------------------------------------------------------------|---|
| 4 | Consulting fees                                                          | X None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X None |
| 6 | Payment for expert testimony                                              | X None |
| 7 | Support for attending meetings and/or travel                               | X None |
| 8 | Patents planned, issued or pending                                        | X None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board          | X None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X None |
|11 | Stock or stock options                                                    | X None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X None |
|13 | Other financial or non-financial interests                                 | X None |

Please place an “X” next to the following statement to indicate your agreement:

_ I certify that I have answered every question and have not altered the wording of any of the questions on this form._
ICMJE DISCLOSURE FORM

Date: Nov 1, 2021

Your Name: Huaqing Wang

Manuscript Title: Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| No. | Relationship/Activity/Interest | Time Frame | Specifications/Comments |
|-----|--------------------------------|------------|-------------------------|
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Since the initial planning of the work | None |
|     | Jiangsu Fosun Pharmaceutical Sales Co. Ltd. | | No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |
| 2   | Grants or contracts from any entity (if not indicated in item #1 above). | past 36 months | None |
| 3   | Royalties or licenses | | None |
|   | Description                                                                 | Agreement | Notes |
|---|-----------------------------------------------------------------------------|-----------|-------|
| 4 | Consulting fees                                                            | ☑️ None   |       |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☑️ None   |       |
| 6 | Payment for expert testimony                                                | ☑️ None   |       |
| 7 | Support for attending meetings and/or travel                                | ☑️ None   |       |
| 8 | Patents planned, issued or pending                                          | ☑️ None   |       |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | ☑️ None   |       |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☑️ None   |       |
| 11| Stock or stock options                                                      | ☑️ None   |       |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☑️ None   |       |
| 13| Other financial or non-financial interests                                  | ☑️ None   |       |

Please place an “X” next to the following statement to indicate your agreement:

☑️ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: Nov 1, 2021

Your Name: Xiuhua Sun

Manuscript Title: Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br>No time limit for this item. | __ __ None<br>Jiangsu Fosun Pharmaceutical Sales Co. Ltd.<br>No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |
| **Time frame: past 36 months** |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | __X__ None |
| 3 | Royalties or licenses | __X__ None |
|   |   |   |
|---|---|---|
| 4 | Consulting fees | X None |
|   |   |   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X None |
|   |   |   |
| 6 | Payment for expert testimony | X None |
|   |   |   |
| 7 | Support for attending meetings and/or travel | X None |
|   |   |   |
| 8 | Patents planned, issued or pending | X None |
|   |   |   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | X None |
|   |   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X None |
|   |   |   |
| 11 | Stock or stock options | X None |
|   |   |   |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X None |
|   |   |   |
| 13 | Other financial or non-financial interests | X None |
|   |   |   |

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.
**ICMJE DISCLOSURE FORM**

Date: Nov 1, 2021

Your Name: Liping Su

Manuscript Title: Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None | Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |
|   | **No time limit for this item.** | | No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |

**Time frame: Since the initial planning of the work**

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |
|   | Description                                                                 |  |   |
|---|-----------------------------------------------------------------------------|---|---|
| 4 | Consulting fees                                                            | X | None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X | None |
| 6 | Payment for expert testimony                                                | X | None |
| 7 | Support for attending meetings and/or travel                                | X | None |
| 8 | Patents planned, issued or pending                                          | X | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | X | None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X | None |
|11 | Stock or stock options                                                      | X | None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X | None |
|13 | Other financial or non-financial interests                                  | X | None |

Please place an “X” next to the following statement to indicate your agreement:

X  I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: Nov 1, 2021
Your Name: Fengting Liu

Manuscript Title: Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br>No time limit for this item. | ___ ___ None<br>Jiangsu Fosun Pharmaceutical Sales Co. Ltd.<br>No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ___ ___ None |
| 3 | Royalties or licenses | ___ ___ None |
| No. | Description                                                                                                           | Option | Answer |
|-----|-----------------------------------------------------------------------------------------------------------------------|--------|--------|
| 4   | Consulting fees                                                                                                       | X      | None   |
| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events           | X      | None   |
| 6   | Payment for expert testimony                                                                                           | X      | None   |
| 7   | Support for attending meetings and/or travel                                                                          | X      | None   |
| 8   | Patents planned, issued or pending                                                                                    | X      | None   |
| 9   | Participation on a Data Safety Monitoring Board or Advisory Board                                                     | X      | None   |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                      | X      | None   |
| 11  | Stock or stock options                                                                                                 | X      | None   |
| 12  | Receipt of equipment, materials, drugs, medical writing, gifts or other services                                       | X      | None   |
| 13  | Other financial or non-financial interests                                                                             | X      | None   |

Please place an “X” next to the following statement to indicate your agreement:

X  I certify that I have answered every question and have not altered the wording of any of the questions on this form.
# ICMJE DISCLOSURE FORM

**Date:** Nov 1, 2021

**Your Name:** Ke Zhao

**Manuscript Title:** Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Jiangsu Fosun Pharmaceutical Sales Co. Ltd. No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| **3** | Royalties or licenses | None |
|   | **Consulting fees** |  | None |
|---|----------------------|--|---|
|   | **Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events** |  | None |
|   | **Payment for expert testimony** |  | None |
|   | **Support for attending meetings and/or travel** |  | None |
|   | **Patents planned, issued or pending** |  | None |
|   | **Participation on a Data Safety Monitoring Board or Advisory Board** |  | None |
|   | **Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid** |  | None |
|   | **Stock or stock options** |  | None |
|   | **Receipt of equipment, materials, drugs, medical writing, gifts or other services** |  | None |
|   | **Other financial or non-financial interests** |  | None |

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: Nov 1, 2021
Your Name: Liye Xu
Manuscript Title: Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br>No time limit for this item. | ___ ___ None<br>Jiangsu Fosun Pharmaceutical Sales Co. Ltd.<br>No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ___ ___ None |
| 3 | Royalties or licenses | ___ ___ None |
Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: Nov 1, 2021

Your Name: Shaohua Wu

Manuscript Title: Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><strong>No time limit for this item.</strong> | ___ ___ None<br>Jiangsu Fosun Pharmaceutical Sales Co. Ltd.<br>No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ____ None |
| 3 | Royalties or licenses | ___ None |
|   |   |   |
|---|---|---|
| 4 | Consulting fees | X None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X None |
| 6 | Payment for expert testimony | X None |
| 7 | Support for attending meetings and/or travel | X None |
| 8 | Patents planned, issued or pending | X None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | X None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X None |
| 11 | Stock or stock options | X None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X None |
| 13 | Other financial or non-financial interests | X None |

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: Nov 1, 2021

Your Name: Teng Song

Manuscript Title: Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | _ _ _ None                                                                 |
|   | Jiangsu Fosun Pharmaceutical Sales Co. Ltd.                                                   | No conflicts of interest to Jiangsu Fosun Pharmaceutical Sales Co. Ltd.          |
|   |                                                                                              |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                     | _ _ _ None                                                                     |
| 3 | Royalties or licenses                                                                         | _ _ _ None                                                                     |

Time frame: Since the initial planning of the work

Time frame: past 36 months
|   |                                                                 |   |
|---|----------------------------------------------------------------|---|
| 4 | Consulting fees                                                 | _X_ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _X_ None |
| 6 | Payment for expert testimony                                     | _X_ None |
| 7 | Support for attending meetings and/or travel                      | _X_ None |
| 8 | Patents planned, issued or pending                                | _X_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _X_ None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _X_ None |
|11 | Stock or stock options                                           | _X_ None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _X_ None |
|13 | Other financial or non-financial interests                        | _X_ None |

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.